Cart
sales@molnova.com
ML390
CAS No. 2029049-79-2
ML390( —— )
Catalog No. M22425 CAS No. 2029049-79-2
ML390 exerts its potent differentiation effect on multiple leukemia models.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 50 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 110 | In Stock |
|
| 50MG | 170 | In Stock |
|
| 100MG | 302 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML390
-
NoteResearch use only, not for human use.
-
Brief DescriptionML390 exerts its potent differentiation effect on multiple leukemia models.
-
DescriptionML390 exerts its potent differentiation effect on multiple leukemia models.
-
In VitroML390 is active with an ED50 of ~2 μM in murine and human AML cell lines. In vitro, treatment of Lys-GFP-ER-HoxA9 cells with ML390 for 48 hr inhibits DHODH activity, leading to the dramatic (>500-fold) accumulation of the upstream metabolite DHO and the depletion of uridine and other downstream metabolites.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2029049-79-2
-
Formula Weight406.4
-
Molecular FormulaC21H21F3N2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:27 mg/mL (66.44 mM)
-
SMILESFC(F)(F)Oc1ccc(cc1)C(=O)NCCC(=O)N[C@@H]1CCCc2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sykes DB et al. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. National Center for Biotechnology Information (US); 2010-2013 Dec 15.
molnova catalog
related products
-
Monoethylglycinexyli...
Used as pharmaceutical intermediates.
-
Upifitamab
Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study cancer.
-
neo-gambogic acid
Neogambogic acid an active ingredient in garcinia can inhibit the growth of some solid tumors and result in an anticancer effect it may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.
